Skip to main content
Premium Trial:

Request an Annual Quote

WuXi NextCode, Google Integrate Genomic Analysis Tools

NEW YORK (GenomeWeb) – WuXi NextCode said today that it has partnered with Google to integrate its genomic data analysis platforms with the Google Cloud platform and genomics research tools.

The partnership, announced at the Healthcare Information and Management Systems Society (HIMSS) annual meeting in Las Vegas, involves hosting WuXi's core suite of capabilities on the Google Cloud Launcher marketplace. Specifically, these capabilities include GORdb, WuXi NextCode secondary analysis, the Sequence Miner case-control research application, and the Clinical Sequence Analyzer clinical interpretation system.

The partners will also integrate Google genomics and research tools with WuXi's platform, beginning with Google's DeepVariant secondary analysis pipeline, and alongside other open-source analysis pipelines and tools available through Google Cloud.

The companies said they plan to launch the first phase of the offering at the BioIT World Conference in May.

The collaboration "aims to create a powerful interoperable suite of capabilities to derive insight from sequence data," Jonathan Sheffi, product manager for genomics and life sciences at Google, said in a statement.

WuXi CEO Hannes Smarason added that the partnership "is an important step towards realizing our vision to provide people and organizations with the best tools for using genomic data, anywhere and at any scale."

In September, WuXi finalized a $240 million Series B financing round with heavy participation from Chinese investors to add artificial intelligence and deep learning to its technology infrastructure, and to seek partnerships in precision medicine and diagnostics.

In January, WuXi and the Mayo Clinic announced a joint venture to provide clinical diagnostic services in China.

Google's DeepVariant is a genomics variant caller that uses deep neural networks to call genetic variants in germline genomes. In December, Google released an open source version of the platform.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.